Somatic Mutational Landscape of Splicing Factor Genes and Their Functional Consequences across 33 Cancer Types

Overview of attention for article published in Cell Reports, April 2018

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (97th percentile)
High Attention Score compared to outputs of the same age and source (92nd percentile)

Mentioned by

news: 13 news outlets
blogs: 1 blog
twitter: 48 X users

facebook: 1 Facebook page
wikipedia: 3 Wikipedia pages

Citations

dimensions_citation: 334 Dimensions

Readers on

mendeley: 588 Mendeley

Summary News Blogs X Facebook Wikipedia Dimensions citations

So far, Altmetric has seen 13 news stories from 13 outlets.

Eisai Enters Into Exclusive Licensing Agreement With Roivant Concerning Investigational Anticancer Agent H3B-8800, a Splicing Modulator

Drug Development & Delivery, 06 Jan 2022

Eisai Co., Ltd. recently announced it has entered into a License Agreement granting the exclusive rights for global research…

EISAI ENTERS INTO EXCLUSIVE LICENSING AGREEMENT WITH ROIVANT CONCERNING INVESTIGATIONAL ANTICANCER AGENT H3B-8800,A SPLICING MODULATOR

PressReleasePoint, 06 Jan 2022

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) announced today that it has entered into a License Agreement…

Eisai Enters Into Exclusive Licensing Agreement with Roivant Concerning Investigational Anticancer Agent H3B-8800, a Splicing Modulator

IT Business Net, 06 Jan 2022

– (JCN Newswire) – Eisai Co., Ltd. announced today that it has entered into a License Agreement granting the exclusive rights…

Eisai Enters Into Exclusive Licensing Agreement with Roivant Concerning Investigational Anticancer Agent H3B-8800, a Splicing Modulator

Biz Wire Express, 06 Jan 2022

ACN Newswire 2022-01-06 TOKYO, Jan 6, 2022 - (JCN Newswire) - Eisai Co., Ltd. announced today that it has entered into a…

Eisai Enters Into Exclusive Licensing Agreement with Roivant Concerning Investigational Anticancer Agent H3B-8800, a Splicing Modulator

JCN Newswire, 06 Jan 2022

- (JCN Newswire) - Eisai Co., Ltd. announced today that it has entered into a License Agreement granting the exclusive rights…

Eisai Enters Into Exclusive Licensing Agreement with Roivant Concerning Investigational Anticancer Agent H3B-8800, a Splicing Modulator

Crwe World, 06 Jan 2022

- (JCN Newswire) - Eisai Co., Ltd. announced today that it has entered into a License Agreement granting the exclusive rights…

Eisai Enters Into Exclusive Licensing Agreement with Roivant Concerning Investigational Anticancer Agent H3B-8800, a Splicing Modulator

DMN Newswire!, 06 Jan 2022

– (JCN Newswire) – Eisai Co., Ltd. announced today that it has entered into a License Agreement granting the exclusive rights…

News story from Finanz Nachrichten on Thursday 06 January 2022

Finanz Nachrichten, 06 Jan 2022

TOKYO, Jan 6, 2022 - (JCN Newswire) - Eisai Co., Ltd.

Ad Hoc News, 06 Jan 2022

Eisai Enters Into Exclusive Licensing Agreement with Roivant Concerning Investigational Anticancer Agent H3B-8800, a Splicing…

Eisai Enters Into Exclusive Licensing Agreement with Roivant Concerning Investigational Anticancer Agent H3B-8800, a Splicing Modulator

MarketScreener, 06 Jan 2022

- (JCN Newswire) - - announced today that it has entered into a License Agreement granting the exclusive rights for global…

Eisai Enters Into Exclusive Licensing Agreement with Roivant Concerning Investigational Anticancer Agent H3B-8800, a Splicing Modulator

AsiaOne, 06 Jan 2022

- (JCN Newswire) - Eisai Co., Ltd. announced today that it has entered into a License Agreement granting the exclusive rights…

H3 Biomedicine Publishes Comprehensive Genomic Landscape Analysis in Cell Reports Revealing Breadth, Frequency and Potential Disease-Driving Significance of Somatic Mutations in RNA Splicing Factor Genes in Multiple Types of Cancer - Press Release

Digital Journal, 03 Apr 2018

CAMBRIDGE, Mass.--(Business Wire)--H3 Biomedicine Inc., a clinical stage biopharmaceutical company specializing in the…

H3 Biomedicine Publishes Comprehensive Genomic Landscape Analysis in Cell Reports Revealing Breadth, Frequency and Potential Disease-Driving Significance of Somatic Mutations in RNA Splicing Factor Genes in Multiple Types of Cancer

Business Wire, 03 Apr 2018

CAMBRIDGE, Mass.--( BUSINESS WIRE )--H3 Biomedicine Inc., a clinical stage biopharmaceutical company specializing in the…

Michigan Publishing

Article Metrics

Somatic Mutational Landscape of Splicing Factor Genes and Their Functional Consequences across 33 Cancer Types

About this Attention Score

Mentioned by

Citations

Readers on

Eisai Enters Into Exclusive Licensing Agreement With Roivant Concerning Investigational Anticancer Agent H3B-8800, a Splicing Modulator

Drug Development & Delivery, 06 Jan 2022

EISAI ENTERS INTO EXCLUSIVE LICENSING AGREEMENT WITH ROIVANT CONCERNING INVESTIGATIONAL ANTICANCER AGENT H3B-8800,A SPLICING MODULATOR

PressReleasePoint, 06 Jan 2022

Eisai Enters Into Exclusive Licensing Agreement with Roivant Concerning Investigational Anticancer Agent H3B-8800, a Splicing Modulator

IT Business Net, 06 Jan 2022

Eisai Enters Into Exclusive Licensing Agreement with Roivant Concerning Investigational Anticancer Agent H3B-8800, a Splicing Modulator

Biz Wire Express, 06 Jan 2022

Eisai Enters Into Exclusive Licensing Agreement with Roivant Concerning Investigational Anticancer Agent H3B-8800, a Splicing Modulator

JCN Newswire, 06 Jan 2022

Eisai Enters Into Exclusive Licensing Agreement with Roivant Concerning Investigational Anticancer Agent H3B-8800, a Splicing Modulator

Crwe World, 06 Jan 2022

Eisai Enters Into Exclusive Licensing Agreement with Roivant Concerning Investigational Anticancer Agent H3B-8800, a Splicing Modulator

DMN Newswire!, 06 Jan 2022

News story from Finanz Nachrichten on Thursday 06 January 2022

Finanz Nachrichten, 06 Jan 2022

TOKYO, Jan 6, 2022 - (JCN Newswire) - Eisai Co., Ltd.

Ad Hoc News, 06 Jan 2022

Eisai Enters Into Exclusive Licensing Agreement with Roivant Concerning Investigational Anticancer Agent H3B-8800, a Splicing Modulator

MarketScreener, 06 Jan 2022

Eisai Enters Into Exclusive Licensing Agreement with Roivant Concerning Investigational Anticancer Agent H3B-8800, a Splicing Modulator

AsiaOne, 06 Jan 2022

H3 Biomedicine Publishes Comprehensive Genomic Landscape Analysis in Cell Reports Revealing Breadth, Frequency and Potential Disease-Driving Significance of Somatic Mutations in RNA Splicing Factor Genes in Multiple Types of Cancer - Press Release

Digital Journal, 03 Apr 2018

H3 Biomedicine Publishes Comprehensive Genomic Landscape Analysis in Cell Reports Revealing Breadth, Frequency and Potential Disease-Driving Significance of Somatic Mutations in RNA Splicing Factor Genes in Multiple Types of Cancer

Business Wire, 03 Apr 2018